Sarepta Therapeutics | SRPT - Ebit


Sarepta Therapeutics reported $-410.08M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Moderna USD -857M 597M Dec/2025
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Tectonic Therapeutic USD -21.52M 374K Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025